Cell therapy will be the backbone of therapies to treat solid tumors.
Roche is testing a mechanism that blocks TIGIT, a receptor capable of shrouding cancer cells from the immune system. Its drug, tiragolumab, binds to the receptor, preventing its deception. Roche added the new drug to its blockbuster medicine Tecentriq in patients with a form of lung cancer.
But during an interim analysis, Roche's regimen failed to meet the study's two key goals. It didn't have a statistically significant impact on the length of time before patients worsened — a measure known as progression-free survival. And it didn't improve overall survival.
Efficient reprogramming of T cells with a CAR in as little as 24 hours in a more simplified manufacturing process without T cell activation or extensive culture outside the body also offers the possibility of expanding where and when these therapies are produced
News 
Market Data 
Discover 
